Parkwalk closes Cisiv investment

We are pleased to announce that the Parkwalk Opportunities EIS Fund and the Parkwalk UK Tech Fund V have led a financing round into Cisiv, an innovative and intuitive software platform for late phase pharmaceutical trials. enables pharmaceutical customers to capture, analyse and share patient data quickly, simply and effectively.

Cisiv has been a pioneering developer of technology solutions for pharmaceutical companies, enabling customers to capture new levels of information on the use of their products and treatments in real world settings.

A specialist in large scale phase IV observational studies, Cisiv’s next generation Web-based software platform enables pharmaceutical customers to capture, analyse and share patient data quickly, simply and effectively. With new levels of intelligence harnessed utilising the Baseline Plus platform, they can demonstrate the effectiveness of treatments and identify additional patient value and healthcare benefits way beyond that which can be achieved through traditional means.